Publisher
Springer Berlin Heidelberg
Reference5 articles.
1. Bradner WT (2001) Mitomycin C: a clinical update. Cancer Treat Rev 27:25–50
2. Fleming RA, Drees J, Loggie BW et al (2002) Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C. Pharmacogenetics 12:31–37
3. Ross D, Siegel D (2004) NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. In: Sies H, Packer L (eds) Methods in enzymology, quinones and quinone Elsevier part B. Elsevier Academic Press, San Diego, pp 115–144
4. Seow HA, Penketh PG, Baumann RP et al (2004) Bioactivation and resistance to mitomycin C. In: Sies H, Packer L (eds) Methods in enzymology, quinones and quinone enzymes part B. Elsevier Academic Press, San Diego, pp 115–144
5. Siegel D, Beall H, Senekowitsch C et al (1992) Bioreductive activation of mitomycin-C by Dt-diaphorase. Biochemistry 31:7879–7885
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. ОСОБЛИВОСТІ ЛІКУВАННЯ НЕПРОТЯЖНИХ СТРИКТУР УРЕТРИ З ВИКОРИСТАННЯМ МІТОМІЦИНУ С;Здобутки клінічної і експериментальної медицини;2023-12-19
2. 10.25040/ecpb2022.01-02;Experimental and Clinical Physiology and Biochemistry;2022-06-22